Clinical practice guidelines constitute one of the most important sources of information and education for physicians. Therefore, establishing rules to develop and appraise such guidelines properly is of increasing importance. This task is served by the AGREE (Appraisal of Guidelines Research and Evaluation) instrument, a questionnaire, which, according to its authors, allows reproducible assessment of guideline quality. The aim of this paper is to allow readers familiarize themselves with such rules of guidelines appraisal. In order to achieve this purpose, we present the actual application of the AGREE instrument using as an example recently published document on postmeal hyperglycemia issued by the International Diabetes Federation.
IntroductIon Clinical practice guidelines (CPG) are becoming one of the basic educational and informational tools for physicians. Scientific associations and other organizations, whether lo cal, national or inter national, develop such docu ments, expecting their members and other users of the guidelines to act according to their recom mendations. Compliance with CPG recommenda tions is sometimes used as an index of health care quality, and the number of CPG is increasing. It is not infrequent that CPG addressing the same clin ical situations are issued independently by differ ent organizations. For 7 . Recommendations includ ed in individual CPG are frequently similar, but sometimes differ. There are numerous reasons for which various scientific associations or orga nizations develop independent documents deal ing with similar clinical situations, starting from local conditions, like availability of drugs, com mon prevention methods, etc, through the needs of specific groups and organizations, to differenc es of opinions.
It is important for users, i.e. physicians, nurses, physiotherapists, patients and other inter ested parties, to have an opportunity to recognize and select CPG with the best odds of benefiting pa tients to whom CPG are applied. However, such choice is difficult, because it is not easy to assess which guidelines are "the best". Many publica tions do not even allow the reader to be precise ly aware to whom they are directed to, what ev idence serve as the basis for recommendations or what was the association between the authors orIGInAL ArtIcLE
International Diabetes Federation document concerning postmeal glycemic control: assessment of quality of clinical practice guidelines using AGREE instrument developers, physicians and health care provid ers attempting to independently assess the qual ity of guidelines before making decisions about implementing their recommendations, and by those involved in education within a given field of medicine.
The AGREE consists of 23 key items organized in 6 domains. Each domain pertains to a sep arate dimension of CPG quality. The first one, scope and purpose (3 items), is to assess the pre cision of the clinical questions. The second one pertains to stakeholder involvement (4 items) and assesses the extent to which the guideline repre sents the views of its intended users. The follow ing group of seven items (rigor of CPG develop ment) relates to the process used to gather and synthesize the evidence, the method to formu late the recommendations and to update them. The fourth domain (clarity and presentation -4 items) deals with the language and format. The following domain (applicability, 3 items) as sesses the organizational, behavioural and cost implications of guideline application. The last covered domain (2 items) is independence, de fining the extent of independence of recommen dations and acknowledgement of possible con flict of inter est from the guideline development group.
Answers to the questions concerning individual quality criteria are rated on a 4point scale (from 1 -"strongly disagree", through 2 -"disagree", 3 -"agree" to 4 -"strongly agree"). Although the as sessment results in individual domains could be found helpful while comparing quality of dif ferent guidelines, it is impossible to determine the threshold score for each domain which recog nizes CPG as "beneficial" or "not beneficial".
To illustrate process described above we pres ent the use of AGREE instrument for the ap praisal of document dealing with postprandi al glycemic control issued by IDF. Individual items of the AGREE instrument are discussed one by one with clarification of their significance and our assessment of the extent to which the IDF guidelines meet a given criterion.
scope and purpose 1 General purpose of CPG has been precise ly defined. 1.1 AGREE clarification: this deals with the po tential health impact of a guideline on society and populations of patients. The overall objective(s) of the guideline should be described in detail and the expected health benefits from the guideline should be specific to the clinical problem. 1.2 IDF guidelines: according to the developers of the analyzed guidelines, the purpose of this guideline is to present data from reports that describe the relationship between postmeal glu cose and the development of diabetic complica tions. Based on these data, recommendations for the appropriate management of postmeal glucose in type 1 and type 2 diabetes have been devel oped. The recommendations are intended to assist and the manufacturers of recommended drugs or devices. The need to establish standard cri teria for guideline assessment has been recog nized by an inter national group of physicians, re searchers and those employed in various health care sectors inter ested in methodology CPG de velopment. The AGREE (Appraisal of Guidelines Research and Evaluation) instrument is the result of their cooperation. 8 This instrument is a ques tionnaire, which, according to its authors, allows reproducible quality assessment of CPG.
The main objective of this paper is to review the rules of assessment and development of guide lines designed to influence clinical practice. It is neither a systematic nor comprehensive review, but more an attempt to introduce the AGREE instrument to readers and demonstration of its practical use for assessment of the recently pub lished document concerning postmeal hypergly cemia issued by the International Diabetes Fed eration (IDF) and available on the IDF website, recently also in Polish (www.idf.org). Its Polish version has also been published in the monthly Medycyna Praktyczna. 9 The International Diabe tes Federation encompasses over two hundred other associations and organizations involved in diabetes therapy, rates among the most repu table and respected diabetic organizations, and its objective is education, prevention and treat ment of diabetes in the world.
AGrEE instrument
The objective of the AGREE instrument is to establish a system for critical appraisal of guidelines. 8 In this framework clin ical practice guidelines are systematically devel oped statements with aim to assist practitioners and patients in deciding appropriate management in specific clinical circumstances. 10 Their purpose is to make explicit recommendations with a defi nite intent to influence what clinicians do. 11 Quality of CPG is meant by the authors of the AGREE instrument as a degree of confi dence that: 1) appropriate steps have been tak en during the process of guideline development to avoid an error leading to formulation of un true recommendations, 2) the recommendations are applicable to patients, whose data have been used to establish the recommendations, and to similar (but potentially slightly different) pa tients, to whom the recommendations may apply in the future, and 3) there is a possibility of in troduction of a given recommendation to clinical practice. According to the AGREE, when assess ing the CPG quality, benefits, harms and costs re sulting from following individual recommenda tions and associated practical issues should be considered. Therefore, a critical look involves as sessment of methods, final wording of individu al recommendations and consideration of factors, which may influence introduction of the guide lines into practice.
The AGREE instrument may be used for assess ment of CPG dealing with any clinical situation. It may be used by health service managers, CPG in the document). The Guideline Development Group included people with considerable expe rience in guideline development, healthcare de velopment and delivery, and people living with diabetes. Geographical representation included all IDF regions and countries in different states of economic development. 4.3 Our assessment: 3 (agree, no details). 5 The patients' views and preferences have been sought. 5.1 AGREE clarification: information about pa tients' experiences and expectations of health care should inform the development of clinical guidelines. 5.2 IDF guidelines: the developers mentioned as follows: "The process involved a broadly based group of people, including people with diabetes (…)." 5. 3 Our assessment: 3 (agree, no details) 6 The target users of the guideline are clear ly defined. 6.1 AGREE clarification: the target users should be clearly defined in the guideline, so they can immediately determine if the guideline is rele vant to them. 6.2 IDF guidelines: "The recommendations are intended to assist clinicians and organizations in developing strategies to effectively manage postmeal glucose in people with type 1 and type 2 diabetes, taking into consideration locally avail able therapies and resources. (…) Logic and clini cal judgment remain critical components of dia betes care and implementation of the guideline recommendations." 6. 3 Our assessment: 3 (agree, no details). 7 The guideline has been piloted among tar get users. 7.1 AGREE clarification: a guideline should have been pretested for further validation amongst its intended end users prior to publication. This process should be documented. 7.2 IDF guidelines: no data available. 7.3 Our assessment: 2 (disagree, no data available).
rigor of development 8 Systematic methods were sued to search for evidence. 8.1 AGREE clarification: "Details of the strate gy used to search for evidence should be provid ed including search terms used, sources consult ed and dates of the literature covered. Sources may include electronic databases (e.g. MEDLINE, EMBASE, CINAHL), databases of systematic re views (e.g. the Cochrane Library, DARE), jour nals, conference proceedings and other guidelines (e.g. the US National Guideline Clearinghouse, the German Guidelines Clearinghouse)." 8. 2 IDF guidelines: "The evidence used in devel oping this guideline included reports from key metaanalyses, evidencebased reviews, clinical trials, cohort studies, epidemio logical studies, animal and basic science studies, position state ments and guidelines (English language only).
clinicians and organizations in developing strate gies to effectively manage postmeal glucose in pa tients with type 1 and type 2 diabetes, taking into consideration locally available therapies and re sources. Postmeal glycemic control in pregnancy has not been addressed in this guideline. 1. 3 Our assessment: 4 points (strongly agree). 2 The clinical question(s) covered by the guide line is(are) specifically described 2.1 AGREE clarification: a detailed description of the clinical questions covered by the guideline should be provided, particularly for the key rec ommendations (see item 17). 2.2 IDF guidelines: "As a basis for developing the recommendations, the Guideline Develop ment Group addressed four questions relevant to the role and importance of postmeal hyperg lycemia in diabetes management. The evidence supporting the recommendations is shown as ev idence statements (with the level of evidence in dicated at the end of the statement)." Those ques tions were as follows: 1) Is postmeal hyperglyce mia harmful? 2) Is treatment of postmeal hyper glycemia beneficial? 3) Which therapies are effec tive in controlling postmeal plasma glucose? 4) What are targets for postmeal glycemic control and how should they be assessed? 2. 3 Our assessment: 4 points (strongly agree). 3 The patients to whom the guideline is meant to apply are specifically described. 3.1 AGREE clarification: there should be a clear description of the target population to be covered by a guideline. The age range, sex, clinical descrip tion, comorbidity may be provided. 3.2 IDF guidelines, according to their devel opers, should deal with postmeal glycemia both in type 1 and type 2 diabetic patients, but do not apply in pregnancy. 3.3 Our assessment: 3 (agree).
stakeholder involvement 4 The guideline development group includes individuals from all the relevant professional groups. 4.1 AGREE clarification: this item refers to the professionals who were involved at some stage of the development process. This may in clude members of the steering group, the research team involved in selecting and reviewing/rating the evidence and individuals involved in formu lating the final recommendations. This item ex cludes individuals who have externally reviewed the guideline (see item 13). Information about the composition, discipline and relevant exper tise of the guideline development group should be provided. 4.2 IDF guidelines: "The process involved a broadly based group of people, including pa tients with diabetes, healthcare professionals from diverse disciplines and people from non governmental organizations. The project was overseen by the Steering Committee (…) and input was provided by the entire Guideline De velopment Group (individual persons specified
studies, the Steering Committee formulated a consensus recommendation." 10. 3 Our assessment: 3 (agree) 11 The health benefits, side effects and risks have been considered in formulating the recom men dations. 11.1 AGREE clarification: the guideline should consider health benefits, side effects, and risks of the recommendations. These may include: sur vival, quality of life, adverse effects, and symptom management or a discussion comparing one treat ment option to another. There should be evidence that these issues have been addressed. 11.2 IDF guidelines: each recommendation was accompanied by an extensive description of evidence and a set of evidencebased state ments which constituted the the basis for the recommendations. 11.3 Our assessment: 3 (agree, however, no dis cussion on costs and nonmonetary expenses in curred by a patient). 12 There is an explicit link between the recom mendations and the supporting evidence. 12.1 AGREE clarification: there should be an ex plicit link between the recommendations and the evidence on which they are based. Each rec ommendation should be linked with a list of ref erences on which it is based. 12.2 IDF guidelines: a link between the recom mendations and the evidence, on which they were based, was clearly identified in the text. 12. 3 Our assessment: 3 (agree formally, recom mendation for treatment not resulting directly from the presented evidence). 13 The guideline has been externally reviewed by experts prior to its publication. 13.1 AGREE clarification: a guideline should be reviewed externally before it is published. Review ers should not have been involved in the devel opment group and should include some experts in the clinical area and some methodo logical ex perts. Patients' representatives may also be in cluded. A description of the methodology used to conduct the external review should be pre sented, which may include a list of the review ers and their affi liation. 13.2 IDF guidelines: "The evidence cited to sup port the recommendations was reviewed by two independent external reviewers who were not part of the Guideline Development Committee. Comments from the external reviewers were then reviewed by the Steering Committee." "The draft guideline was sent out for a wider external review to IDF member associations, global and regional IDF elected representatives, inter ested profession als, industry and others on IDF contact lists, for a total of 322 invitations. Thirtyeight comments from 20 external reviewers from five of the seven IDF regions (Africa, South East Asia, Western Pa cific, North America, Europe) were received. These A scientific writer with knowledge of diabetes ob tained relevant reports through a computerized search of available data using the PubMed and other search engines; scanning incoming jour nals in the medical library and reviewing the ref erences in pertinent s, major textbooks and syl labi from national and inter national meetings on the subjects of diabetes, using relevant title and text words (e.g. postprandial, postmeal, hy perglycemia, mealtime, selfmonitoring, oxida tive stress, inflammation) as search criteria. Ev idence relating to both postmeal and postchal lenge plasma glucose was reviewed and cited as appropriate. A review of recent guidelines, posi tion statements and recent articles not identified in the universal search was also conducted to ob tain additional information that was potentially applicable to the questions. An electronic data base was created to include full reference informa tion for each report; abstracts for most of the re ports were included in the database. Members of the Steering Committee were asked to iden tify any additional reports or publications rel evant to the questions. In total, 1,659 reports were identified." 8. 3 Our assessment: 4 (strongly agree). 9 The criteria for selecting the evidence are clearly described. 9.1 AGREE clarification: criteria for including/ excluding evidence identified by the search should be provided. These criteria should be explicitly de scribed and reasons for including and excluding evidence should be clearly stated. For example, guideline authors may decide to only include ev idence from randomised clinical trials and to ex clude articles not written in English. 9.2 IDF guidelines: the authors used all avail able evidence and based their recommendations on those with highest quality. For this purpose they used the evidencegrading criteria system developed by the Scottish Intercollegiate Guide lines Network (SIGN, see tAbLE; for more infor mation on methods see the document on: www. idf.org).
Note: the evidencegrading criteria system mentioned above gives the highest ranks to ran domized controlled trials, which pertain main ly to therapeutical questions and lower to prog nosis trials, which were the basis for the answer to question number 1. 9.3 Our assessment: 4 (strongly agree). 10 The methods used for formulating the rec ommendations are clearly described. 10.1 AGREE clarification: there should be a de scription of the methods used to formulate the recommendations and how final decisions were arrived at. Methods include, among others, a voting system, formal consensus techniques (e.g. Delphi, Glaser techniques). Areas of disagree ment and methods of resolving them should be specified. Selfmonitoring of blood glucose should be con sidered because it is currently the most practical method for monitoring postmeal glycemia.
Efficacy of treatment regimens should be mon itored as frequently as needed to guide thera py towards achieving the postmeal plasma glu cose target. 15. 3 Our assessment: 2 (disagree; see Addition al comments). 16 The different options for management of the condition are clearly presented. 16.1 AGREE clarification: a guideline should con sider the different possible options for screening, prevention, diagnosis or treatment of the condi tion it covers. 16.2 IDF guidelines: as stated above, a num ber of treatment options described by the au thors cover almost every hyperglycemia control method. 16. 3 Our assessment: 4 (agree). 17 Key recommendations are easily identifiable. 17.1 AGREE clarification: users should be able to find the most relevant recommendations easily. These recommendations answer the main clinical questions that have been covered by the guideline. They can be identified in different ways. For ex ample, they can be summarised in a box, typed in bold, underlined or presented as flow charts or algorithms. 17.2 IDF guidelines: the above mentioned sug gestions have been fulfilled. 17. 3 Our assessment: 4 (agree). 18 The guideline is supported with tools for application. 18.1 For a guideline to be effective it needs to be disseminated and implemented with addi tional materials. These may include for example, a summary document, a quick reference guide, educational tools, leaflets for patients, comput er support. 18.2 IDF guidelines: no materials mentioned above. 18. 3 Our assessment: 2 (disagree; see Addition al comments).
comments were reviewed by the Steering Com mittee and considered in developing the final document." 13. 3 Our assessment: 4 (agree). 14 A procedure for updating the guideline is provided. 14.1 AGREE clarification: guidelines need to re flect current research. There should be a clear statement about the procedure for updating the guideline. For example, a timescale has been given, or a standing panel receives regularly up dated literature searches and makes changes as required. 14.2 IDF guidelines: IDF considers review and update within three years. 14. 3 Our assessment: 3 (agree, although the up date intent is not precise).
clarity and presentation 15 The recommendations are specific and unambiguous. 15.1 AGREE clarification: a recommendation should provide a concrete and precise description of which management is appropriate in which sit uation and in what patient group, as permitted by the body of evidence. However, evidence is not always clear cut and there may be uncertainty about the best management. In this case the un certainty should be stated in the guideline. 15.2 IDF guidelines: below we present recom mendations corresponding to the four main questions: Question 1 Is postmeal hyperglycemia harmful? recommendation 1 Postmeal hyperglycemia is harmful and should be addressed. Question 2 Is treatment of postmeal hypergly cemia beneficial? recommendation 2 Implement treatment strate gies to lower postmeal plasma glucose in patients with postmeal hyperglycemia. Question 3 Which therapies are effective in con trolling postmeal plasma glucose? recommendation 3 A variety of both non pharmaco logic and pharmaco logic therapies should be considered to target postmeal plas ma glucose. Question 4 What are targets for postmeal glyce mic control and how should they be assessed?
tAbLE Evidence-grading criteria according to Scottish Intercollegiate Guidelines Network 1 + + High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias 1 -Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 2 + + High-quality systematic reviews of case-control or cohort studies; high-quality case control or cohort studies with a very low risk of confounding bias and a high probability that the relationship is causal 2 + Well-conducted case-control or cohort studies with a low risk of confounding bias or chance and a moderate probability that the relationship is causal; well-conducted basic science with a low risk of bias 2 -Case-control or cohort studies with a high risk of confounding bias or chance and a significant risk that the relationship is not causal 3 Non-analytic studies (for example s, case series)
Expert opinion
Abbreviations: RCT -randomized controlled trials
Amylin Pharmaceuticals, Eli Lilly and Company, LifeScan, Inc., Merck & Co. Inc, Novo Nordisk A/S, Roche Diagnostics GmbH, Roche Pharmaceuti cals. These companies did not take part in the de velopment of the guideline. However, these and other commercial organizations on IDF's commu nications list were invited to provide comments on draft versions of the guideline." 22. 3 Our assessment: 3 (agree, although the lev el of authors' independence from the industry is usually much more complex than "no external funding" recommended by the AGREE). 23 Conflict of inter est of guideline development members have been recorded. 23.1 AGREE clarification: there are circumstanc es when members of the development group may have conflicts of inter est. For example, this would apply to a member of the development group whose research on the topic covered by the guide line is also funded by a pharmaceutical compa ny. There should be an explicit statement that all group members have declared whether they have any conflict of inter est. 23. 2 IDF guidelines: members of the Guideline Development Committee have declared relevant dualities of inter est in the topic and in relation ships with commercial enterprises, governments and nongovernmental organizations. No fees were paid to the Guideline Development Com mittee members in connection with the current activity. 23. 3 Our assessment: 3 (agree to a degree sim ilar to other guidelines and documents, proba bly in the future the authors would be required much more detailed declaration).
Final comments Analysis of IDF guidelines using the AGREE instrument allowed us to make certain observations concerning both documents.
First, the examination of the utility of the AGREE instrument suggests that it should not be used to specifically determine clinical usefulness of CPG or to make unambiguous decisions about adher ing to their recommendations. Instead, AGREE should rather be used to identify the domains, which should be more closely considered by both the CPG users and the persons responsible for their update. Numerical scores attributed to in dividual domains will lack significance with out reference to clinical context, which requires thorough expertise. Clinical context is an essen tial component of the process of CPG develop ment and assessment. Clinical questions them selves, which should be answered by individu al recommendations, are of fundamental signif icance. In the case of the IDF guidelines consid ered here, clinical questions concern postmeal blood glucose; it could, however, be noted that al though the evidence of harm of postmeal hyper glycemia is not in doubt, it has not been demon strated by authors of IDF guidelines that treat ment aiming at its reduction was associated with a decrease in mortality caused by diabetic compli cations. This observation follows the fact that it The potential organizational barriers in apply ing the recommendations have been discussed. 19.1 AGREE clarification: applying the recom mendations may require changes in the current organisation of care within a service or a clin ic which may be a barrier to using them in dai ly practice. Organisational changes that may be needed in order to apply the recommendations should be discussed. 19.2 IDF guidelines: taking into account the low level of precision and explicitness of recom mendations, the above aspects have not been considered. 19. 3 Our assessment: 2 (disagree, not applicable). 20 The potential cost implication of applying recommendations have been considered. 20.1 AGREE clarification: the recommendations may require additional resources in order to be applied. For example, there may be a need for more specialised staff, new equipment, expen sive drug treatment. These may have cost impli cations for health care budgets. There should be a discussion of the potential impact on resourc es in the guideline. 20.2 IDF guidelines: the cost issue has been treated superficially: "Although cost will remain an important factor in determining appropriate treatments, controlling glycemia is ultimately much less expensive than treating the complica tions of diabetes." 20. 3 Our assessment: 2 (disagree). 21 The guideline presents key review criteria for monitoring and/or audit purposes. 21.1 AGREE clarification: measuring the ad herence to a guideline can enhance its use. This requires clearly defined review criteria that are derived from the key recommendations in the guideline. 21.2 IDF guidelines: treatment goals are clear ly specified: HbA 1c <6.5%, premeal (fasting) plas ma glucose <5.5 mg/dl, 2hour postmeal plasma glucose <7.8 mg/dl. 21. 3 Our assessment: 3 (agree, although prac tical aspects of reaching those goals remain uninvestigated).
Editorial independence 22
The guideline is ly independent from the funding body. 22.1 AGREE clarification: some guidelines are developed with external funding (e.g. Govern ment funding, charity organisations, pharma ceutical companies). Support may be in the form of financial contribution for the whole develop ment, or for parts of it, e.g. printing of the guide lines. There should be an explicit statement that the views or inter ests of the funding body have not influenced the final recommendations. Please note: If it is stated that a guideline was developed without external funding, then you should an swer "strongly agree". 22. 2 IDF guidelines: "This activity was support ed by unrestricted educational grants from:
